First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, Susan Prohaska et al.|Journal of Clinical Oncology|2019Cited by 590
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancerEverett J. Moding, Maximilian Diehn, Yufei Liu et al.|Nature Cancer|2020Cited by 369
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y. Nabet, Maximilian Diehn, Mohammad Shahrokh Esfahani et al.|Cell|2020Cited by 360
<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase InhibitionMichael S. Binkley, Maximilian Diehn, Young-Jun Jeon et al.|Cancer Discovery|2020Cited by 172
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discoveryShin‐Heng Chiou, Mark M. Davis, Diane Tseng et al.|Immunity|2021Cited by 134